Matteo SCARABELLI

After a Phd in Philosophy, Matteo started building his expertise in the pharmaceutical market as responsible for the involvement of patients in Regulatory approval and access decisions for orphan drugs. He has then contributed designing the strategy of rare disease organisations across Europe for the new EU HTA, also participating in the genesis and in the inter-institutional negotiations of the HTA Regulation. For three years now, he has been working at the heart of the pharmaceutical industry's efforts to prepare for the new European HTA setting and its implementation into national pricing and reimbursement systems.